Payment overview · 2025
General Payments
$1,097.33
15 reported records · 7 companies
Healthcare provider profile · identity verified
Rex H Wu, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NEW YORK, NY · NPI 1861456196
Verified facts
What the public records show
CMS Open Payments records show Rex H Wu, M.D. received $1,097.33 in general payments during 2025 across 15 reported records.
Madrigal Pharmaceuticals accounted for 39.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta, Vemlidy.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 222 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 389 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $432.62 | 39.4% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $150.00 | 13.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $138.78 | 12.7% | 7 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $125.00 | 11.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $122.43 | 11.2% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$110.96 | 10.1% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $17.54 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,097.33 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $432.62 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $138.78 | 7 | 2025 |
Source payment records
|
|||||
| Vemlidy Normalized: vemlidy |
Drug | Gilead Sciences, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $122.43 | 1 | 2025 |
Source payment records
|
|||||
| INTERSTIM Normalized: interstim |
Device | Medtronic, Inc. | $110.96 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $17.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Vemlidy vemlidy |
2025 | Vemlidy | 2024 | 69 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
222 | 54 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
389 | 382 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
74 | 43 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1857 | 407 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1575 | 380 |
| Losartan Potassium | Losartan Potassium | 1060 | 254 |
| Metoprolol Succinate | Metoprolol Succinate | 771 | 188 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 502 | 132 |
| Tamsulosin Hcl | Tamsulosin Hcl | 469 | 118 |
| Vascepa | Icosapent Ethyl | 443 | 96 |
| Metformin Hcl | Metformin Hcl | 418 | 96 |
| Raloxifene Hcl | Raloxifene Hcl | 418 | 91 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 389 | 382 |
| Diclofenac Epolamine | Diclofenac Epolamine | 382 | 68 |
| Ammonium Lactate | Ammonium Lactate | 311 | 92 |
| Fluticasone Propionate | Fluticasone Propionate | 309 | 147 |
| Trazodone Hcl | Trazodone Hcl | 294 | 92 |
| Hydrochlorothiazide | Hydrochlorothiazide | 286 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 248 | 52 |
| Finasteride | Finasteride | 244 | 53 |
| Tradjenta | Linagliptin | 227 | 46 |
| Farxiga | Dapagliflozin Propanediol | 222 | 54 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 221 | 145 |
| Gabapentin | Gabapentin | 207 | 47 |
| Omeprazole | Omeprazole | 202 | 119 |
| Azelastine Hcl | Azelastine Hcl | 188 | 106 |
| Glipizide Er | Glipizide | 184 | 42 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 180 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 171 | 68 |
| Hydrocortisone | Hydrocortisone | 168 | 93 |
| Eliquis | Apixaban | 165 | 33 |
| Januvia | Sitagliptin Phosphate | 165 | 33 |
| Glimepiride | Glimepiride | 156 | 34 |
| Allopurinol | Allopurinol | 144 | 33 |
| Montelukast Sodium | Montelukast Sodium | 142 | 47 |
| Donepezil Hcl | Donepezil Hcl | 141 | 23 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 136 | 101 |
| Metformin Hcl Er | Metformin Hcl | 134 | 31 |
| Ezetimibe | Ezetimibe | 127 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 122 | 33 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 120 | 49 |
| Alendronate Sodium | Alendronate Sodium | 119 | 30 |
| Jardiance | Empagliflozin | 119 | 22 |
| Lisinopril | Lisinopril | 117 | 32 |
| Naproxen | Naproxen | 115 | 86 |
| Furosemide | Furosemide | 105 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 103 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 103 | 37 |
| Nifedipine Er | Nifedipine | 98 | 19 |
| Linzess | Linaclotide | 93 | 23 |
| Atenolol | Atenolol | 92 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 91 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 89 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 85 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 84 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 83 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 80 | 33 |
| Procto-Med Hc | Hydrocortisone | 80 | 25 |
| Icosapent Ethyl | Icosapent Ethyl | 79 | 22 |
| Meclizine Hcl | Meclizine Hcl | 78 | 55 |
| Prolia | Denosumab | 76 | 45 |
| Famotidine | Famotidine | 75 | 29 |
| Carvedilol | Carvedilol | 74 | 16 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 74 | 43 |
| Celecoxib | Celecoxib | 72 | 39 |
| Folic Acid | Folic Acid | 71 | 17 |
| Vemlidy | Tenofovir Alafenamide | 69 | suppressed |
| Telmisartan | Telmisartan | 68 | 16 |
| Entecavir | Entecavir | 63 | suppressed |
| Acarbose | Acarbose | 58 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 57 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 56 | 13 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 55 | 38 |
| Meloxicam | Meloxicam | 55 | 37 |
| Azithromycin | Azithromycin | 53 | 49 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 52 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 11 |
| Myrbetriq | Mirabegron | 52 | suppressed |
| Potassium Chloride | Potassium Chloride | 52 | 25 |
| Jentadueto | Linagliptin/Metformin Hcl | 48 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 47 | suppressed |
| Memantine Hcl | Memantine Hcl | 46 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 13 |
| Sucralfate | Sucralfate | 46 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 45 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Colchicine | Colchicine | 43 | 17 |
| Sertraline Hcl | Sertraline Hcl | 43 | suppressed |
| Mirtazapine | Mirtazapine | 40 | suppressed |
| Dutasteride | Dutasteride | 39 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 37 | 16 |
| Cephalexin | Cephalexin | 37 | 37 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 37 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Baclofen | Baclofen | 36 | 21 |
| Simvastatin | Simvastatin | 35 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 34 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | suppressed |
| Lidocaine | Lidocaine | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | suppressed |
| Livalo | Pitavastatin Calcium | 30 | suppressed |
| Creon | Lipase/Protease/Amylase | 29 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 29 |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 21 |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Silodosin | Silodosin | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 25 | suppressed |
| Loperamide | Loperamide Hcl | 25 | 23 |
| Cholestyramine | Cholestyramine (With Sugar) | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Clonidine | Clonidine | 22 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 17 |
| Clobetasol Propionate | Clobetasol Propionate | 20 | suppressed |
| Fluocinonide | Fluocinonide | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Prednisone | Prednisone | 19 | 15 |
| Sevelamer Carbonate | Sevelamer Carbonate | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 19 |
| Tramadol Hcl | Tramadol Hcl | 19 | 13 |
| Dapagliflozin | Dapagliflozin Propanediol | 18 | 11 |
| Topiramate | Topiramate | 18 | suppressed |
| Clotrimazole | Clotrimazole | 17 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Ciclopirox | Ciclopirox | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 14 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Clonazepam | Clonazepam | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 12 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Metformin Er Osmotic | Metformin Hcl | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,097.33 · 15 records | Madrigal Pharmaceuticals | BREZTRI, Fluad, INTERSTIM, Kerendia, REZDIFFRA, TRELEGY ELLIPTA, Vemlidy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error